纤连蛋白介导视网膜血管生成中的内皮-间充质转化
该研究在氧诱导视网膜病变(OIR)小鼠模型中通过RNA测序分析基因表达,发现内皮-间充质转化(EndoMT)是病理性视网膜血管生成的早期事件,纤连蛋白(FN1)是内皮细胞中上调最显著的EMT相关基因。siRNA抑制纤连蛋白可在体外阻止VEGF诱导的血管生成,并在OIR模型中减少病理性血管生成;作者认为靶向纤连蛋白可能提供与抗VEGF治疗协同的新策略。
要点
- EndoMT在视网膜血管生成早期即发生,EMT与血管生成基因集显著相关。
- FN1是内皮细胞中上调最显著的EMT相关基因。
- siRNA抑制纤连蛋白可阻止体外VEGF诱导的血管生成并减少OIR模型病理性血管生成。
核心结论
- EndoMT是病理性视网膜血管生成的关键早期事件,纤连蛋白是其中的关键介导因子。
- 作者认为靶向纤连蛋白可能提供与抗VEGF治疗协同的新策略,以更有效治疗糖尿病视网膜病变(DR)和早产儿视网膜病变(ROP)的病理性血管生成,尤其是单独抗VEGF治疗反应不佳的病例。
研究设计与样本
- 对氧诱导视网膜病变(OIR)小鼠模型的视网膜组织进行RNA测序(RNA-seq)以分析基因表达模式。
- 使用基因集富集分析(GSEA)检查上皮-间充质转化(EMT)与血管生成基因集之间的相关性。
- 评估内皮细胞中纤连蛋白(FN1)的表达,并通过siRNA介导的敲低在体外血管生成实验和OIR模型中评估其功能。
主要发现
- EndoMT发生在视网膜血管生成发展的早期,EMT与血管生成基因集之间存在显著相关性。
- FN1被鉴定为内皮细胞中上调最显著的EMT相关基因。
- siRNA介导的纤连蛋白抑制在体外有效阻止VEGF诱导的血管生成,并在OIR模型中减少病理性血管生成。
临床怎么用
- 原文未据此给出临床推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: The purpose of this study was to investigate the role of endothelial-mesenchymal transition (EndoMT) in pathological retinal angiogenesis and identify key molecular mediators in retina angiogenesis. METHODS: RNA sequencing (RNA-seq) was performed on retinal tissue from an oxygen-induced retinopathy (OIR) mouse model to analyze gene expression patterns. The Gene Set Enrichment Analysis was used to examine the correlation between epithelial-mesenchymal transition (EMT) and angiogenesis gene sets. Fibronectin (FN1) expression was evaluated in endothelial cells, and its function was assessed through siRNA-mediated knockdown in both in vitro angiogenesis assays and the OIR model. RESULTS: EndoMT occurred early in retinal angiogenesis development, with significant correlation between EMT and angiogenesis gene sets. FN1 was identified as the most significantly upregulated EMT-related gene in endothelial cells. The siRNA-mediated inhibition of fibronectin effectively prevented VEGF-induced angiogenesis in vitro and reduced pathological angiogenesis in the OIR model. CONCLUSIONS: EndoMT is a crucial early event in pathological retinal angiogenesis, with fibronectin serving as a key mediator. Targeting fibronectin may provide a novel therapeutic strategy that could synergize with anti-VEGF treatments to more effectively treat pathological angiogenesis in diabetic retinopathy (DR) and retinopathy of prematurity (ROP), particularly in cases of poor response to anti-VEGF therapy alone.
引用
- Liu D, Meng Z, Jin C, et al. Fibronectin Mediates Endothelial-to-Mesenchymal Transition in Retina Angiogenesis. Invest Ophthalmol Vis Sci. 2025. PMID: 40042877. doi:10.1167/iovs.66.3.10
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。